Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/377
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | BUYSE, Marc | - |
dc.contributor.author | MOLENBERGHS, Geert | - |
dc.contributor.author | BURZYKOWSKI, Tomasz | - |
dc.contributor.author | RENARD, Didier | - |
dc.contributor.author | GEYS, Helena | - |
dc.date.accessioned | 2004-10-25T12:03:19Z | - |
dc.date.available | 2004-10-25T12:03:19Z | - |
dc.date.issued | 2000 | - |
dc.identifier.citation | Drug Information Journal, 34(2). p. 447-454 | - |
dc.identifier.issn | 0092-8615 | - |
dc.identifier.uri | http://hdl.handle.net/1942/377 | - |
dc.description.abstract | Prentice proposed a definition of surrogate endpoints and operational criteria for their validation. Freedman supplemented these criteria with the proportion explained, which is supposed to represent the proportion of the treatment effect upon the true endpoint which is mediated by the surrogate endpoint. In this paper, we argue that the proportion explained should be replaced by other quantities, such as the relative effect linking the effects of treatment on both endpoints and an individual-level measure of agreement between both endpoints. The latter quantity carries over naturally when data are available on several randomized experiments, while the former can be extended to be a trial-level measure of agreement between the effects of treatment of both endpoints. This approach suggests a new definition of surrogacy, and allows one to predict the effect of treatment upon the true endpoint, given its observed effect upon the surrogate endpoint. | - |
dc.language.iso | en | - |
dc.publisher | DRUG INFORMATION ASSOCIATION | - |
dc.rights | Copyright (C) 2000 Drug Information Association Inc. | - |
dc.subject | Clinical trials | - |
dc.subject | Clustered data | - |
dc.subject | Surrogate Markers | - |
dc.subject.other | meta-analysis; surrogate endpoint; validation | - |
dc.title | Statistical validation of surrogate endpoints: problems and proposals | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 454 | - |
dc.identifier.issue | 2 | - |
dc.identifier.spage | 447 | - |
dc.identifier.volume | 34 | - |
local.bibliographicCitation.jcat | A1 | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.bibliographicCitation.oldjcat | A1 | - |
dc.identifier.isi | 000087220200013 | - |
dc.identifier.url | https://www.researchgate.net/profile/Marc_Buyse/publication/241646459_Statistical_Validation_of_Surrogate_Endpoints_Problems_and_Proposals/links/0c96052d22f6dd1de5000000/Statistical-Validation-of-Surrogate-Endpoints-Problems-and-Proposals.pdf | - |
item.fulltext | With Fulltext | - |
item.contributor | BUYSE, Marc | - |
item.contributor | MOLENBERGHS, Geert | - |
item.contributor | BURZYKOWSKI, Tomasz | - |
item.contributor | RENARD, Didier | - |
item.contributor | GEYS, Helena | - |
item.fullcitation | BUYSE, Marc; MOLENBERGHS, Geert; BURZYKOWSKI, Tomasz; RENARD, Didier & GEYS, Helena (2000) Statistical validation of surrogate endpoints: problems and proposals. In: Drug Information Journal, 34(2). p. 447-454. | - |
item.accessRights | Restricted Access | - |
item.validation | ecoom 2001 | - |
crisitem.journal.issn | 0092-8615 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Statistical_Validation_of_Surrogate_Endpoints_Prob.pdf Restricted Access | Published version | 142.9 kB | Adobe PDF | View/Open Request a copy |
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.